MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Clinical trials for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests potential Game-Changer for debilitating bowel disease
Disease control Recruiting nowThis large, late-stage study is testing whether a new drug called Afimkibart can help people with moderate to severe ulcerative colitis. Researchers will compare the drug against a placebo in 350 participants to see if it reduces symptoms and improves gut health over 12 weeks. Th…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 02, 2026 00:26 UTC
-
New hope for kids with severe bowel disease
Disease control Recruiting nowThis study is testing whether a new medication called afimkibart can help children aged 2-17 who have moderate to severe ulcerative colitis, a painful bowel disease. Researchers want to see if the treatment can bring the disease under control and keep it controlled for a year. Th…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New infusion therapy aims to tame debilitating bowel disease
Disease control Recruiting nowThis study is testing whether a drug called vedolizumab, given as an IV infusion, can help control moderate to severe ulcerative colitis over the long term. It will involve about 402 Chinese adults whose symptoms haven't improved enough with standard treatments. Participants will…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC